Ex-Boyfriend's Chilling Prelude to Murder of Sydney Water Polo Coach Uncovered in Inquest

Australia’s Therapeutic Goods Administration (TGA) has approved the weight loss drug Wegovy for the treatment of heart disease in overweight and obese patients, effective December 2024. The drug, containing semaglutide 2.4 mg, is now indicated as a complementary therapy for adults with cardiovascular disease who have a high body mass index, aiming to reduce the risk of heart attack, stroke, or death.
The decision follows promising results from the Select trial, involving 17,604 participants globally, which revealed a 20% reduction in heart attack or stroke incidence for patients taking Wegovy compared to those given a placebo. According to Prof Stephen Nicholls, the trial lead in Australia, this approval marks a significant advancement in utilizing GLP-1 receptor agonists for non-diabetic patients at risk of heart disease.
However, the TGA's approval does not automatically lead to subsidization under the Pharmaceutical Benefits Scheme (PBS), which some experts consider critical to ensuring patient access given the substantial budget implications of increased prescriptions.